GABAA receptor agent 8 (compound 5e) is a potent positive modulator of the GABAA receptor, exhibiting anticonvulsant activity in both in vitro and in vivo studies, with low neurotoxicity, indicating its potential in epilepsy research [1].

GABAA receptor agent 8 (compound 5e) demonstrates anticonvulsant activity, evidenced by an IC50 of 0.334 μM in the 4-AP induced hyper-excitability model [1]. Additionally, this compound enhances GABA-induced activation of the GABAA1 receptor in a dose-dependent manner over a range of 0.01-100 μM and a duration of 0-140 seconds, with an EC50 of 12.02 μM.

GABAA receptor agent 8 (compound 5e) demonstrates anticonvulsant efficacy in mice, exhibiting an effective dose (ED50) of 40.95 mg/kg and a toxic dose (TD50) of 372.39 mg/kg [1]. This agent specifically mitigates seizures induced by pentylenetetrazol (PTZ) without affecting those caused by maximal electroshock (MES) in mice [1].